Anthony Marucci, Celldex CEO
Taking aim at Xolair, Celldex offers a positive early readout for their rival drug — but researchers have a lot of work remaining
The researchers at Celldex are flagging some positive data from a small early stage trial for their drug barzolvolimab in patients with moderate to severe …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.